On November 13, 2017, the non-invasive continuous monitoring system on blood pressure per heartbeat developed by Zhejiang Mailian Medical Equipment Co., Ltd. has passed the special examination and approval of Type II innovative medical device from Zhejiang Food and Drug Administration. The administration will be giving priority in accordance with the principles of “early intervention”, “person-in-charge”, and “scientific approval”. The time spent on these five processes, i.e., products register and inspection, registered quality system verification, technical review, administrative approval, etc. will be expecting 30% and up time reduction respectively.